Pharmamarketeer
overig

What biosim threat? Roche wins another reprieve as FDA stiff-arms Novartis Rituxan copy

9 mei 2018
FiercePharma

Cue the relief in Basel: Roche’s Rituxan just got another biosim break. Rival drugmaker Novartis says its knockoff version didn’t pass muster at the FDA, and that setback follows another for would-be Rituxan copycat Celltrion. The upshot? No U.S. biosims are likely this year.

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)